MET and breast cancer: Overexpression of miR-199a-3p targets c-Met and mTOR, affecting increased sensitivity to doxorubicin and also leading to G1 phase arrest, resulting in reduced invasion and increased doxorubicin-induced apoptosis in BC cells [112].